{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:33:08Z","timestamp":1791048788660,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,11,8]],"date-time":"2007-11-08T00:00:00Z","timestamp":1194480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To study characteristics of women using herbal drugs and the possible impact of use in early pregnancy on pregnancy outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data on the use of herbal drugs during pregnancy were obtained from the Swedish Medical Birth Register during the period 1st July 1995 to end of 2004. Women who reported use of herbal drugs were compared to all women giving birth during the period. Outcome variables were prematurity, birth weight, Apgar score, number of infants in delivery and congenital malformations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 860\u2009215 women in the register, 787 (0.9%) reported use of herbal drugs during early pregnancy. The most frequently used herbal drugs were Floradix\u00ae (iron\u2010rich herbs), ginseng and valerian. Use of such drugs was independently associated with high maternal age, normal weight and 14\u201315 years of education. Risk factors for valerian differed from those for other herbal drugs, for example with respect to maternal smoking and country of birth. Concomitant drug use was common and the most frequently used drugs were multivitamins, folic acid, cardiovascular drugs (mainly antihypertensive drugs), non\u2010steroid anti\u2010inflammatory drugs (NSAIDs), analgesics and psycholeptics. None of the infant characteristics studied were influenced significantly by the mother's use of the examined herbal drugs during early pregnancy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The most commonly reported herbal drugs used during pregnancy were Floradix\u00ae (iron\u2010rich herbs), ginseng and valerian. No signs of unfavourable effect on pregnancy outcome were seen. The number of exposures, however, was low and therefore effects on rare outcomes (e.g. specific malformations) cannot be excluded. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.1527","type":"journal-article","created":{"date-parts":[[2007,11,8]],"date-time":"2007-11-08T13:47:35Z","timestamp":1194529655000},"page":"151-159","source":"Crossref","is-referenced-by-count":70,"title":["Use of herbal drugs during early pregnancy in relation to maternal characteristics and pregnancy outcome"],"prefix":"10.1002","volume":"17","author":[{"given":"Lone","family":"Holst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedvig","family":"Nordeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein","family":"Haavik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,1,31]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"World Health Organisation:Fact sheet No 134: Traditional Medicine.2003; Bern.http:\/\/www.who.int\/mediacentre\/factsheets\/fs134\/en\/index.html[26th June 2007]."},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7050.131a"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.945"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102393\u20106\u201021"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(01)01250-9"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.223"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200203000-00039"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1054\/yctnm.2001.0620"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20102005\u2010873235"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2001.116688"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1300\/J157v03n04_02"},{"key":"e_1_2_1_13_2","first-page":"954","article-title":"Complementary medicine use during pregnancy. Interviews with 48 women in a hospital antenatal ward","volume":"21","author":"Byrne MJ","year":"2002","journal-title":"Aust Pharm"},{"key":"e_1_2_1_14_2","first-page":"1008","article-title":"The effect of traditional herbal medicines on pregnancy outcome\u2014The King Edward VIII Hospital experience","volume":"87","author":"Mabina MH","year":"1997","journal-title":"S Afr Med J"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/140349489001800209"},{"key":"e_1_2_1_16_2","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology.http:\/\/www.whocc.no\/atcddd\/[24th September 2007]."},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01719316"},{"key":"e_1_2_1_18_2","first-page":"823","volume-title":"Developmental and Reproductive Toxicology. A Practical Approach","author":"Hood RD","year":"2006"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.18.1569"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1741-4520.2005.00062.x"},{"key":"e_1_2_1_21_2","volume-title":"Herbal Medicines","author":"Barnes J","year":"2002"},{"key":"e_1_2_1_22_2","volume-title":"The Desktop Guide to Complementary and Alternative Medicine","author":"Ernst E","year":"2006"},{"key":"e_1_2_1_23_2","unstructured":"Physicians' Desk Reference (PDR) for Herbal Medicines. Thomson PDR Montvale USA 2004."},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deg401"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1389-9457(99)00015-5"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.02.026"},{"key":"e_1_2_1_27_2","volume-title":"A Reference Guide to Fetal and Neonatal Risk. Drugs in Pregnancy and Lactation","author":"Briggs GG","year":"2002"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1391"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0001-6349.2005.00648.x"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161150-00002"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.1527","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.1527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T21:19:14Z","timestamp":1699996754000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.1527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,31]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1002\/pds.1527"],"URL":"https:\/\/doi.org\/10.1002\/pds.1527","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,31]]}}}